By: Benzinga
UPDATE: JP Morgan Cuts PT to $7 on Arena Pharmaceuticals on Belviq Launch Concerns
JP Morgan maintained Arena Pharmaceuticals (NASDAQ: ARNA ) with a Neutral rating and lowered the price target from $8.00 to $7.00. JP Morgan commented, "We continue to see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here